Determinations of total cytokine concentration in biological fluids by immunoassays face two major problems: the biochemical heterogeneity of the analyte and the interference of cytokine-binding proteins. We developed an ultrasensitive enzyme immunoassay for interleukin-6 (IL-6), using monoclonal antibodies and acetylcholinesterase as the tracer enzyme. The antibodies recognized recombinant and glycosylated forms of lL-6 equally. The antibodies measured dimeric recombinant IL-6, yet we could not detect IL-6oligomers in plasma samples. We investigated the potential interference of soluble IL-6 receptor (slL-6R), which is present at high concentrations in plasma samples (1 to 2 nmol/L). Heat treatment of the sample obviated the slL-6R interference. Using calibrators in a plasma matrix, we demonstrated by fractionation, dilution, and recovery experiments that the immunoassay accurately measured total lL-6 in both normal and pathological serum and plasma samples. IL-6 is also the major paracrine growth factor of multiple myeloma in vivo, as evidenced by the efficacy of therapy with anti-IL-6 antibodies (4). Circulating IL-6 bioactivity has been detected during the course of multiple myeloma, and increased IL-6 is associated with fnlminant disease (5). The implication of IL-6 as a growth factor in other oncologicdisorders (6) , as well as in autoimmune and rheumatoid diseases, is currently being investigated (7). ' 5Nonstandard abbreviations: IL,-6,interleukin 6; rhlL-6, recombinant human IL-6; sIL-6R, soluble IL-6 receptor;AchE, acetylcholinesterase;EU, Ellman unit; EIA, enzyme immunoassay, PBS, phosphate-buffered saline; BSA, bovine serum albumin; SMCC, N-sucinimidyl-4-(N-maleidomethyl)-cyclohexane-1-carboxylate; SDS-PAGE, sodiumdodecyl sulfate-polyacrylamide gel electrophoresis; and NIBSC, National Institute of Biological Standards and Controls.
and different IL-6 isoforms may differ quantitatively in their ability to generate an IL-6 response (9,
10). Numerous immunoassays
for IL-6 have been designed to circumvent this major drawback and to measure IL-6 molarity in biological samples (11-16); however, lack of sensitivity is a limitation of immunoassays. Another problem is that the monoclonal antibodies used in the assay might differ in their recognition of the different IL-6 isoforms. Immunoassays are sensitive also to interference by plasma components.
In the case of IL-6, the soluble form of the p80 component of the receptor (sIL-6R) binds to IL-6 in solution and is present at a high concentration in serum (17) (18) (19) (20) (21) . Therefore, sIL-6R might be a major source of interference in immunoassays of IL-6.
We have designed an ultrasensitive enzyme immunoassay (EIA) of IL-6 based on the use of acetylcholinesterase (AchE; EC 3.1.1.7), taking advantage of the high turnover of this enzyme. The antibodies used in this assay were analyzed exhaustively with regard to recognition of circulating IL-6 isoforms and to interference by sIL-6R. We conclude that total IL-6 can be measured accurately in plasma samples. Conversely, this assay, with its well-defined monoclonal antibodies, provides a tool to investigate the biochemical heterogeneity of IL-6 in biological fluids.
Materials and Methods

Apparatus
We performed the solid-phase EJA with standard mlcrotitration equipment, including an automated plate washer and a microplate spectrophotometer (both from SLT, Salzburg, Austria). Gel filtration chromatography was performed either with an integrated low-pressure system or by FPLC (both from Pharmacia, Uppsala, Sweden). Cells were transfected by electroporation, with use of a GeneZapper from IBI (Madison, WI). In the bioassay, the cells were harvested with a cell harvester (Skatron, Lier, Norway) and their radioactivity was determined with a Betamatic beta counter (Kontron, Z#{252}-rich, Switzerland). 
Gel filtration chromatography.
Gel filtration chroma- IL-6 bioassay. Biological activity of human IL-6 was evaluated by using the murine IL-6-dependent plasmacytoma cell line B9(8). B9 cells were cultured for 12 h in the absence of IL-6 and further cultured with IL-6-contathing samples for 48 h in microtiter plates in RPMI 1640 medium supplemented with FCS (50 milL). The cultures were then incubated with 0.25 Ci of [3H]thymidine (Amersham) per well for 8 h. The cells were then harvested, and the radioactivity incorporated in the cell pellets was determined with the beta counter. A standard range of serial dilutions of rhIL-6 was included in every experiment. Specific activity, defined as the IL-6 dose that gave one-half of the maximal B9 proliferation,
Assay of plasma and serum samples. For serum assays, we collected 2.5 mL of blood in a clean glass tube and let this stand at room temperature for 1 h. We then centrifuged the samples (1700g, 30 mm, 4#{176}C) , collected the upper two-thirds of the supernates (-1 mL), and stored these at -20#{176}C until assay. Plasma samples were collected into EDTA-containing Vacutainer Thbes (Beckton Dickinson), centrifuged at 4#{176}C without delay, and stored at -20#{176}C until assay.
Before the bioassay, the plasma and serum samples were diluted in culture medium and decomplemented by heating for 20 mm at 56#{176}C. Normal samples were obtained from healthy volunteers.
Pathological serum samples from sepsis patients were kindly provided by Eric Plaisant (Hopital Ambroise Pare, Marseffle).
Resufts
Specificity of the Assay The following cytokines were tested for their possible interference in the immunoassay:
IL1-t ILl-fl,IL-2,
tumor necrosis factor-o and granulocyte-macrophage colony stimulating factor. The minimal detectable concentrations of these potentially cross-reactive analytes were >1000 p.g/L for all cytokines tested. Furthermore, adding these cytokines at 100 gIL to rhIL-6 solutions did not affect the signal. For this purpose, we serially diluted in EIA buffer samples of unglycosylated, E. coli-derived rhIL-6 and samples of glycosylated IL-6 from the transfected cell line BW.C12 and analyzed these by the immunoassay. The dilution curves were parallel for all forms tested, indicating that the assay recognized equally well the glycosylated and unglycosylated forms ( Fig. 2A) . band under reducing conditions (data not shown). Eventually, when rhIL-6 samples were heated for 20 min at 56#{176}C and subsequently fractionated, we obtained one single immunoreactive peak at 20 kDa (Fig. 3A) . These results demonstrated that the two major inimunoreactive peaks consisted of monomeric and dimeric forms of rhlL-6, respectively.
Recognition
The conversion of the purified dimeric form into monomer by heat treatment doubled the immunoreactivity of the sample. This indicates that the EIA actually measures the molarity of the different forms of rhIL-6 rather than the mass concentration. We ersmined the recognition of the two forms quantitatively in the EIA. The purified dimeric rhIL-6 could be detected in an homologous sandwich assay that used the same antibody for capture and detection of the analyte, whereas the monomeric form was not detected in this system. Dilution curves were parallel for the monomeric and the dimeric forms, in either the homologous or in the standard heterologous EJA, suggesting that both forms were recognized with similar affinity.
Multimeric
forms of natural IL-6. The recognition of oligomeric forms of IL-6 was analyzed by fractionation of IL-6-containing samples and by means of the homologous sandwich assay system described above. Glycosylated IL-6 produced by BW.C12 transfected cells eluted as a single peak corresponding to a monomeric form (Fig. 3B) ;using the homologousEJA, we failed to detect oligomeric forms in this preparation. When acute-phase plasma was fractionated under the same conditions, most immunoreactivity eluted as monomeric IL-6, but we detected an additional minor high-Me (Fig. 3C) we determined that sIL-6R was a thermosensitive protein and was completely destroyed when heated for 20 mm at 56#{176}C, whereas monomeric rhIL-6 was not affected by this procedure.We took advantage of this differential thermosensitivity of IL-6 and sIL-6R in an attempt to dissociate IL-6/sIL-6R complexes and to measure total sample IL-6. When different amounts of sIL-6R were preincubated with rhIL-6 (monomer), as described above, heat treatment of the preformed complexes led to almost complete recovery of the signal in the immunoassay (Fig. 4) .
Measurementof IL-6 in Plasma
We investigated the accuracy of the immunoassay for the measurement of IL-6 in sera or plasma. In these 
-).
After 30 mm at 56'C, the same preparation was eluted as a puremonomer (-) (B and C). The sampleswere fractionated by S200 chromatography,and each fractionwas tested either for lmmunoreactMty with the IL-S EIA (-) or for bloactMty in the 99 assay (- 3 g/L) . When a saturating amount of IL-6 was present, the sample was diluted with normal serum before iinmunoassay. The accuracy of the assay was tested in analytical recovery and dilution experiments.
In serum and EDTA-plasma from healthy volunteers, the recovery of added E. coli-derived rhJL-6 was satisfying (mean 95.3%, SD 7.0%; 16 samples). Dilution analysis was then performed with samples from sepsispatients. In these experiments, the circulating IL-6 was recognized as well as standard rhIL-6 (Fig. 2B) . Finally, the assay linearity was determined by mixing IL-6-containing sera (up to 200 ng'L) with IL-6-negative samples. The immunoassay was found to be linear in this range.
Sensitivity of the Immunoassay
A preparation of E. coli-derived rhIL-6 calibrated with NIBSC 88/5 14 was serially diluted in either a pool of IL-6-negative normal sera or EIA buffer. Then we analyzed every rhIL-6 solution in 12 simultaneous determinations with the immunoassay.
The detection limit, defined as the minimal concentration of IL-6 that produces a signal equal to the nonspecific background plus 2 SD, was as low as 0.3 ng'L when rhlL-6 was diluted in buffer, 3 clearly demonstrated by plotting precision profiles for different reading times (Fig. 5A) . Longer incubation times led to a limit precision profile, which may be considered as the intrinsic profile of the immunoassay. Note that the signal remained linear for the lowest concentrations of IL-6, thus allowing quantitative determinations around the detection limit, as outlined in Fig.   5B . In view of the optimal catalytic properties of AchE, which provides a continuous signal for many hours, the working range of the assay may be adapted to the actual concentration of IL-6 in the samples. isoforms of equal molecular mass. However, as evidenced by immunoprecipitation experiments, the three major isoforms described in the literature are recognized by both of the assay antibodies we used. Moreover, both AH64 and AH65 blocked the biological activity of glycosylated IL-6. We assume, therefore, that the glycosylation sites are outside the antibody epitopes. Macromolecular heterogeneity was also reported: Dimeric IL-6 was found in recombinant preparations (35) , and large amounts of high-M,, immunoreactive and bioactive IL-6 oligomers were reported in plasma samples (9,10) . We chose to study oligomer recognition in the model system of recombinant E. coli-derived IL-6, though this system is not of physiological relevance. Our experiments showed that both assay antibodies recognized dimeric IL-6 as well as monomeric IL-6. From these results we assume that the immunoassay detects naturally occurring IL-6 oligomers. In fractionation experiments with acute-phase plasmas, we detected only a minor high-Me immunoreactive component. The elution of B9 bioactivity correlated with the elution of immunereactivity, indicating that the major active forms were actually found in the main 20-to 30-kDa immunoreactive peak. Taken together, these results prompt us to conclude that the immunoassay detects all IL-6 isoforms and that the predominant circulating form active on the B cell lineage is monomeric. According to May et a!. ported (40) . We focused on the IL-6/sIL-6R interaction. Thus, the fraction of IL-6 that is bound to sIL-6R is functionally relevant and must be measured in an IL-6
DIscussIon
assay. The average normal concentration of sIL-6R in plasma is 1-2 nmol/L (21, 27), and the dissociation constant of IL-6/sIL-6R interaction is close to 1.5 nmol/L (20, and our own unpublished data). Hence in normal plasma, sIL-6R is in great molar excess to IL-6 (sIL-6111 IL-6 ratio = 2 x 10), and -50% of circulating bioavailable IL-6 is then bound to sIL-6R. We observed a 30% decrease of the signal when 2 nmol/L sIL-6R was added to a 10 pmol/L solution of IL-fl in buffer. The standards being diluted in a pool of plasma containing 1.5 nmol/L sIL-6R, the interference due to sIL-6R would be expected to occur only in some samples. This provides a means to cope with sIL-6R interference and to measure total IL-6 directly.
The assay dose/response curve obtained when IL-6 was diluted in plasma was close to the dose/response curve in ELA buffer containing 1.5nmol/L sIL-6R. Thus, the presence of sIL-6R may account for most of the plasma effect. 
